Epidemiology of Whooping Cough/ Pertussis

2023-2024





The disease first appeared in France in 1414. The first epidemic was described in 1578 by **Guillaume de Baillou**

The disease is endemic worldwide and continues to be a public health concern despite established pertussis immunization programs with high coverage.

Pertussis is acute highly infectious disease of children.



Bordetella Pertussis (Pertussis bacillus)

The organism was first isolated by Jules Bordet and Octave Gengou in 1906.




Reservoir of Infection

Man, cases whether typical, or mild not showing the paroxysms, [No Carriers].

The organisms find exit in respiratory discharges.

PROF DR Najlaa Fawzi



Modes of Transmission


- 1. Direct droplet infection; direct case contact infection is the main mode of spread.
- **2.** Air borne infection, with in short distance of the case.
- 3. Using soiled articles & fomites.

In vaccinated populations, bacteria are frequently brought home by an older sibling.

When the source of whooping cough was identified, mothers were responsible for 30-40% of infant infections.

6

75% Of Suspected Sources For Infant Pertussis Cases Were Family Members



PROF DR Najlaa Fawzi



Average 9-10days (range 6-20days)

Clinical Picture

Pertussis is a local disease of respiratory tract.

- In apparent [atypical] Cases: do not show the typical paroxysms, and so are difficult to diagnose clinically, they are met with partly immune children & young adults.
 - Typical untreated Cases: they pass through the following stages:

CLINICAL COURSE

Catarrhal stage: 1-2 weeks, insidious onset, with slight or no fever; upper respiratory catarrh; rhinitis, sneezing, dry irritating cough & lacrimation.

This is the stage of maximum infectivity

Paroxysmal stage: paroxysmal attacks of spasmodic coughing.

- Can be more frequent at night
- Each attack followed by characteristic whoop with expectoration of tenacious clear mucus & vomiting.
- The cough paroxysm consists of a short series of expiratory bursts, followed by an inspiratory gasp, which results in the typical "whoop".
- Iasting 1-6 weeks but may persist for up to 10 weeks.

Maximum complications occur in this stage.

Convalescence:

•During the convalescence stage recovery is gradual and the cough becomes less paroxysmal and disappears in 2-3 weeks (recovery may take weeks to months).

Treated Cases Chemotherapy eliminates infection and the case progressively improves in short time.

		2	3	4	5	6	7	8	9	10	11	12
Stage 1 Catarrha May last 1 weeks	al Stage	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	nptoms gious	: runn	y nose, l	ow-grad	e fever, m	 ild, occ	asional c	:ough – H	łighly	ļ
		Stage 2 - Paroxysmal Stage Lasts from 1-6 weeks; may extend to 10 weeks										
	- 1	Symptoms: fits of numerous, rapid coughs fol- lowed by "whoop" sound; vomiting and exhaus- tion after coughing fits (called paroxymsms)						La	Stage 3 - Convalescent Stage Lasts about 2-3 weeks; susceptible to other respiratory infections for many			
						Recovery is gradual. Coughing les						



Untreated Cases: from onset of disease, and for 3 weeks after onset of characteristic paroxysmal coughing, infectivity is highest during the early catarrhal stage.

Treated Cases: specific antibiotics therapy eliminates infection in about 7 days after starting treatment.

Period Of Communicability Of Pertussis

- > Whooping cough is highly infectious, spreading to 70 to 100% of susceptible household contacts and 50 to 80% of susceptible school contacts.
- Persons with pertussis are most infectious during the catarrhal period and the first 2 weeks after cough onset (i.e., approximately 21 days).

Complications

Major complications of pertussis in infants and children are of 3 types:

- > Pulmonary
- Neurologic (acute pertussis encephalopathy)
- > Nutritional

In develop settings, complications of pertussis such as bronchopneumonia occur in about 6% of infected children; infants aged.

In infants —complications from whooping cough are more severe and may include:

✓Pneumonia

- ✓ Slowed or stopped breathing
- ✓ Dehydration or weight loss due to feeding difficulties
- **√Seizures**
- ✓ Brain damage

Because infants and toddlers are at greatest risk of complications from whooping cough, they're more likely to need treatment in a hospital. Complications can be life-threatening for infants younger than 6 months old.

Possible complications of pertussis in older children and adults


Complications in older children and adults are usually much less serious that those in infants and young children.

May include:

- Nose bleeds and burst blood vessels in the white of the eye from intense bouts of coughing
- > Bruised ribs as a result of intense coughing
- > Hernia due to intense coughing
- > A swollen face
- > Ulcers on the tongue and mouth
- > Ear infections such as otitis media

Pertussis Mortality

- Death from pertussis occurs rarely but young infants <6 months of age are most at risk
- Risk factors for mortality
 - Female sex
 - BW <2500 grams</p>
 - Apgar score <8</p>
 - Mother with <12 years of education



APGAR SCORING SYSTEM

	0 Points	1 Point	2 Points	Points totaled
Activity (muscle tone)	Absent	Arms and legs flexed	Active movement	
Pulse	Absent	Below 100 bpm	Over 100 bpm	
Grimace (reflex irritability)	Flaccid	Some flexion of Extremities	Active motion (sneeze, cough, pull away)	
Appearance (skin color)	Blue, pale	Body pink, Extremities blue	Completely pink	
Respiration	Absent	Slow, irregular	Vigorous cry	

PROF DR Najlaa Fawzi

Excellent condition 7-10

Diagnosis

Clinical: based on finding the typical paroxysmal attacks of coughing, ending in high pitched inspiratory whoop.

> Laboratory:

Diagnosis of pertussis should only be attempted in patients with symptoms compatible with pertussis, such as prolonged coughing with paroxysms and/or whooping or choking.

In infants, older vaccinated children, adolescents and adults the clinical course may not be typical, and prolonged coughing may be the only symptom.

In these cases, diagnosis of pertussis requires laboratory methods for confirmation

The organism is demanding, surviving only a few hours in respiratory secretions and thus requiring special media for culture.

The diagnosis of pertussis is made by isolation of B pertussis in culture. A polymerase chain reaction (PCR) test also can be performed.

- The culture specimen should be obtained during the <u>first 2</u> weeks of cough by using <u>deep nasopharyngeal aspiration</u>
- For PCR testing, nasopharyngeal specimens should be taken at 0-3 weeks following cough onset
- The CDC recommends a combination of culture and PCR assay if a patient has a cough <u>lasting longer than 3 weeks</u>
- Early serial monitoring of white blood cell (WBC) counts is necessary
 PROF DR Najlaa Fawzi
 21




1. Begins at birth, no maternally acquired immunity ??WHY


2.The highest around school age [5-7] years, and almost all become immune by the age of 15 years.

3.Sex ;incidence and fatality being more in females than in males.

4-The whooping cough vaccine received as a child in time wears off. This leaves most teenagers and adults susceptible to the infection during an outbreak — and there continue to be regular outbreaks.

In recent years, many cases of whooping cough have been recognized in adults and adolescents due to waning immunity. These individuals are a significant source for the transmission of infection to infants.





PROF DR Najlaa Fawzi

5-A child who has never been vaccinated against pertussis, is 13 times more likely to suffer from an infection of *Bordetella pertussis* than is a child who is up-to-date on his or her vaccines.

6-More than 80% of cases occurred in fully vaccinated children. Children only partially vaccinated were 1.9 times more likely to contract whooping cough than fully vaccinated peers.

Epidemiology of Whooping Cough


Endemic worldwide

Despite a long-standing vaccination program, pertussis remains highly prevalent in many countries.

- Pertussis is the least well controlled of all vaccine-preventable diseases, and epidemics occur every 3–5 years.
- According to the Centers for Disease Control and Prevention (CDC), there are an estimated 24.1 million cases of whooping cough and about 160,700 deaths in children younger than age 5 years worldwide annually.

- Infants younger than age 1 year continue to have the highest rates of pertussis.
- In 2018, pertussis incidence per 100,000 was 72.3 in infants younger than age 6 months and 32.7 in infants age 6 to 12 months, compared to 1.4 in persons age 20 years or older.

•Pertussis is a major cause of childhood morbidity and mortality in developing countries, where an estimated 50 million cases and 300,000 deaths occur each year. During the last decades, multiple epidemics of pertussis took place in many countries including those with high vaccination coverage



Reasons for rising incidence

 Waning of vaccine- and infection-induced immunity (wanes after 5-10 years)

~ 15 years after active disease ~ 5-10 years after vaccination

Waning immunity due to replacement of the highly effective but reactogenic whole-cell vaccines with acellular vaccines, the wP vaccines gave children a more lasting immunity than aP

- Increased recognition and reporting
- Availability of better diagnostic tests
- ?Use of less potent pertussis vaccines
- ? Emergence of vaccine-resistant strains


□ The switch from wP to aP for primary infant immunization was proposed as at least partially responsible for that reappearance.

The World Health Organization (WHO), therefore, recommended considering the switch only if, in the national immunization schedules, large numbers of doses including several boosters could be assured.

Countries currently using aP vaccines may continue using them but should consider the need for additional booster doses and strategies to prevent early childhood mortality upon pertussis re-emergence. □ Centers for Disease Control and Prevention researchers in USA say that the vaccine used for whooping cough is less effective because the bacteria behind the disease has mutated.

The researchers analyzed lab samples from whooping cough patients between 2000 and 2013 and found that Bordetella pertussis, which causes whooping cough, has undergone genetic changes over time.

PREVENTION and CONTROL



Prevention

General preventive measures of respiratory [droplet] infection must be followed, but specific prevention is the effective measures by immunization [active & seroprophylaxis], and chemoprophylaxis.

Active Immunization: By Pertussis vaccine.

Two types of vaccines against pertussis exist: whole-cell vaccines (wP), developed in the 1940s, containing the entire inactivated Bordetella pertussis organism, and acellular vaccines (aP)

The main aim of pertussis vaccination is to reduce the risk of severe pertussis in infancy.

33

THEY SHOULD BE FAMOUS They created the first whooping cough vaccine

Grace Eldering Loney Gordon


Pearl Kendrick

ALMOST NO ONE KNOWS THEIR NAMES You can change that by sharing this poster



- Vaccination against pertussis does not give lifelong immunity
- Individuals who have had pertussis can become re-infected and spread infection to others
- This spread of infection is important particularly in children too young to be vaccinated

PROTECT AGAINST WHOOPING COUGH"



The w(w=whole cell) vaccines are produced from cultures of selected B. pertussis strains that are subsequently killed, usually by heating or treatment with formalin.

>wPs are still used for primary vaccination doses in developing countries.

- These vaccines are generally not used in older children because of concerns regarding reactogenicity.
- > Vaccines containing wP must not be frozen. They should be stored at 2–8 °C.

Vaccine safety

Vaccination with wP vaccines is frequently associated with minor local and systemic adverse reactions (1 in 2–10 vaccinations), such as local redness and swelling, induration, fever and agitation.

 Prolonged crying and febrile convulsions are not uncommon

 As local reactions tend to increase with age and with the number of injections, wP-containing vaccines are usually not recommended for use in children aged ≥7 years, adolescents and adults. To reduce the reactogenicity of booster doses, aP-containing vaccines with reduced concentrations of the antigens have been formulated for use in adolescents and adults.

Vaccination of health-care workers

Several studies have shown that health-care workers (HCWs) are at increased risk of pertussis, and that transmission in health-care settings poses substantial risk of infection for infants and immunocompromised individuals

Give aP vaccine.

Vaccination during pregnancy

If a mother has a dose of whooping cough vaccine from 20 weeks of pregnancy, this can provide good protection for the baby until they can have their first vaccine at 6 weeks of age. aP vaccine is used for pregnant women.

Age &dose	Vaccine
After birth(1 st week	
2 Months 1 st dose	(الخماسي)[Panta -1] (DwPT+ Hib , HBV)& Rota virus & OPV-1+ Pneumococcal(PCV13-1)
4Months 2 nd dose	Panta-2 [DwPT, Hib , HBV] , IPV-1 Rota virus-2 OPV-2+ Pneumococcal (PCV13-2)
6Months 3 rd dose	[D wPT, Hib , HBV] . IPV-2, OPV-3 + Pneumococcal(PCV13-3)
9Months	
12 Months	
18 Months	[DwPT +Hib] الرباعي [Tetra MMR , OPV 1 st booster , vit A (200.000IU)
4- 6 Years	الثلاث <i>ي</i> DwPT (<u>2ND booster dose</u>), OPV, Vit A(200.000IU)

- Health Education: of parents, for basic knowledge of the disease & the protective value and precautions with the vaccination.
- Seroprophylaxis: antipertussis immunoglobulin; 2.5 ml IM, can be given to protect susceptible intimate contacts, especially infants & young children. Protective value, however, is not certain. So far, there is no evidence of its efficacy in well-controlled trials,

so chemoprophylaxis is preferred.

Chemoprophylaxis:

Oral erythromycin or clarithromycin can be given in proper dosage, for 5 days after the last contact with the case.

- Antibiotics can be used for 2 purposes in the control and prevention of pertussis :
- 1. Treatment to modify clinical symptoms of pertussis by administering to symptomatic patients
- **2.Prevention of secondary spread of pertussis by administering to:**
- Symptomatic patients (treatment) and interrupting infectiousness and transmission by eliminating the organism from the respiratory system.
- Asymptomatic contacts (prophylaxis) and interrupting transmission by eliminating any organisms that may have been contracted

 If within 3 weeks of exposure, prophylaxis recommended for all household and close contacts (regardless of age or vaccination status).

- ✓ If 3 weeks have passed since exposure, still consider prophylaxis for households with high risk contacts:
 - > Young infants
 - > Pregnant women
 - > People who have contact with young infants

Pediatric Clinicians Play a Critical Role in TREATING INFANT PERTUSSIS



CONTROL

Control measures are taken for:

- ✓ Cases
- ✓ Contacts
- ✓ School

1- Control of Cases :

\checkmark Reporting to local health authority.

✓ <u>Isolation at home</u>; practically difficult to fulfill, since the majority of cases are mild, with no or slight fever, they usually move in the community and go to school, and so spread infection to exposed susceptible children.

✓ Infants younger than 6 months generally require hospitalization

Approximately half of babies less than 1 year old who get pertussis need treatment in the hospital.

- Cases should be removed from the presence of young infants, especially non immunized infants, until the patients have received at least 5 days of a minimum 14 days course of antibiotics.
- ✓ Suspected cases who do not receive AB should be isolated for 3 weeks.
- ✓ Concurrent disinfection of respiratory discharges; & any soiled objects, and terminal cleaning & airing of the room.

47

Treatment

- Primary role of treatment is to accelerate clearance of organisms and limit transmission
 - Treat as late as 3 weeks after cough onset if age >1 year
 - Treat as late as 6 weeks after cough onset if age <1 year
- Treatment during catarrhal or early paroxysmal stage may modify duration and severity of illness
- Otherwise treatment generally does not affect clinical course

□ The antibiotic <u>erythromycin</u> or <u>azithromycin</u> is a front-line treatment .

Newer <u>macrolides</u> are frequently recommended due to lower rates of side effects.

- Trimethoprim- sulfamethoxazole may be used in those with allergies to first line agents or in infants who have a risk of pyloric stenosis from macrolides.
- Effective treatments of the <u>cough</u> associated with this condition have not yet been developed

✓ Proper feeding

Release: pupils can return to school; with proper chemotherapy [one week after starting AB], with no ,or not sure of chemotherapy [3weeks after onset of whooping stage, and satisfactory general condition]

2- Control of Contacts :

Protection of contacts: passive immunization is not effective, and the initiation of active immunization to protect against recent exposure is also not effective.

Inadequately immunized household contacts less than 7 years of age should be excluded from day care center for 21 days after last exposure or until cases & contacts receive 5 days course of AB

Close contacts under 7 years who not received 4 doses of pertussis vaccine or have not receive a dose within 3years should be given a dose as soon as after exposure as possible.

A 7 days course of erythromycin or clarithromycin for household & other close contacts, regardless of immunization status and age is recommended.

Control of Pertussis in School: when case appear in school:

- Isolation of cases and return to school according to case management.
- Segregation of susceptible family contacts for 2 wks.
- Surveillance of susceptible school contacts for 2wk, to exclude any; once respiratory catarrh appears
- Surveillance of all school children until no more cases appear [case finding]
- Chemoprophylaxis of susceptible family & school contacts

References

1-Daniela Hozbor. Update on Epidemiology, Diagnosis, and Treatment of Pertussis. Pertussis DOI: 10.5772/intechopen.72847

2-Michael D Decker, Kathryn M Edwards. Pertussis (Whooping Cough) The Journal of Infectious Diseases, Volume 224, Issue Supplement_4, 1 October 2021, Pages S310–S320, https://doi.org/10.1093/infdis/jiaa469